SCM
Silverarc Capital Management Portfolio holdings
AUM
$489M
This Quarter Return
+18.55%
1 Year Return
+71.55%
3 Year Return
+1,109.63%
5 Year Return
–
10 Year Return
–
AUM
$444M
AUM Growth
+$444M
(+9.5%)
Cap. Flow
-$7.11M
Cap. Flow
% of AUM
-1.6%
Top 10 Holdings %
Top 10 Hldgs %
47.12%
Holding
80
New
13
Increased
27
Reduced
19
Closed
11
Top Buys
| 1 |
Insmed
INSM
|
$15.2M |
| 2 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$11.9M |
| 3 |
Vaxcyte
PCVX
|
$6.63M |
| 4 |
Protagonist Therapeutics
PTGX
|
$6.6M |
| 5 |
Veracyte
VCYT
|
$6.41M |
Top Sells
| 1 |
MORF
Morphic Holding, Inc. Common Stock
MORF
|
$16.6M |
| 2 |
Nuvalent
NUVL
|
$9.64M |
| 3 |
Evogene
EVGN
|
$8.51M |
| 4 |
Celldex Therapeutics
CLDX
|
$7.81M |
| 5 |
Corbus Pharmaceuticals
CRBP
|
$7.81M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Nuvalent
NUVL
$5.52B
| $38M | 8.53% | 371,441 -94,269 | -20% | -$9.64M |
|
2
Merus
MRUS
$4.98B
| $31.7M | 7.13% | 635,439 +11,811 | +2% | +$590K |
|
|
3
Insmed
INSM
$28.8B
| $25.4M | 5.7% | 347,695 +207,695 | +148% | +$15.2M |
|
4
Avidity Biosciences
RNA
$5.99B
| $21.8M | 4.91% | 475,555 -42,179 | -8% | -$1.94M |
|
5
Erasca
ERAS
$445M
| $19M | 4.26% | 6,946,488 -870,438 | -11% | -$2.38M |
|
6
Akero Therapeutics
AKRO
$3.74B
| $18.4M | 4.12% | 639,840 +14,753 | +2% | +$423K |
|
|
7
Veracyte
VCYT
$2.39B
| $16M | 3.6% | 470,565 +188,317 | +67% | +$6.41M |
|
8
Rhythm Pharmaceuticals
RYTM
$6.85B
| $13.4M | 3.01% | 255,578 +70,916 | +38% | +$3.72M |
|
9
Cogent Biosciences
COGT
$1.69B
| $13.2M | 2.96% | 1,221,362 +15,148 | +1% | +$164K |
|
|
ITCI
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $12.2M | 2.75% | 167,110 -25,235 | -13% | -$1.85M |
|
|
CNTA
11
Centessa Pharmaceuticals
CNTA
$2.25B
| $11.9M | 2.67% | +744,592 | New | +$11.9M |
|
12
UroGen Pharma
URGN
$900M
| $11.4M | 2.57% | 901,129 -200,871 | -18% | -$2.55M |
|
13
Oric Pharmaceuticals
ORIC
$994M
| $11.3M | 2.53% | 1,099,490 +23,678 | +2% | +$243K |
|
|
PSTX
14
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $10.5M | 2.37% | 3,687,548 +79,549 | +2% | +$228K |
|
|
VRNA
15
Verona Pharma
VRNA
$9.16B
| $10M | 2.25% | 348,866 +44,233 | +15% | +$1.27M |
|
16
Alnylam Pharmaceuticals
ALNY
$58.5B
| $9.84M | 2.21% | 35,774 -226 | -0.6% | -$62.2K |
|
17
Geron
GERN
$893M
| $8.18M | 1.84% | 1,801,561 +802,291 | +80% | +$3.64M |
|
18
Syndax Pharmaceuticals
SNDX
$1.41B
| $7.29M | 1.64% | 378,746 +8,746 | +2% | +$168K |
|
|
19
Vaxcyte
PCVX
$4B
| $6.91M | 1.55% | 60,500 +58,000 | +2,320% | +$6.63M |
|
20
KalVista Pharmaceuticals
KALV
$678M
| $6.65M | 1.49% | 574,558 +13,675 | +2% | +$158K |
|
|
21
Protagonist Therapeutics
PTGX
$3.67B
| $6.6M | 1.48% | +146,657 | New | +$6.6M |
|
22
C4 Therapeutics
CCCC
$185M
| $6.54M | 1.47% | 1,147,891 -294,950 | -20% | -$1.68M |
|
23
Sarepta Therapeutics
SRPT
$1.78B
| $6.4M | 1.44% | 51,245 +9,245 | +22% | +$1.15M |
|
24
Biodesix
BDSX
$62.6M
| $6.34M | 1.42% | 3,561,094 +1,752,135 | +97% | +$3.12M |
|
25
Elutia
ELUT
$96.7M
| $6.27M | 1.41% | 1,645,808 +42,228 | +3% | +$161K |
|